| 1 | Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises | 4.4 | 31 | Citations (PDF) |
| 2 | Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers | 4.5 | 8 | Citations (PDF) |
| 3 | Use of artificial intelligence chatbots in clinical management of immune-related adverse events 2024, 12, e008599 | | 31 | Citations (PDF) |
| 4 | Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy | 4.6 | 3 | Citations (PDF) |
| 5 | Evolving Management of Stage IV Melanoma | 4.4 | 13 | Citations (PDF) |
| 6 | Development and validation of an LC–MS/MS method to measure the BRAF inhibitors dabrafenib and encorafenib quantitatively and four major metabolites semi-quantitatively in human plasma | 3.0 | 5 | Citations (PDF) |
| 7 | The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors | 3.8 | 11 | Citations (PDF) |
| 8 | Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity | 1.5 | 19 | Citations (PDF) |
| 9 | Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT | 6.8 | 30 | Citations (PDF) |
| 10 | CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel Disease-Specific MRI Measures of Tumor Burden | 2.3 | 10 | Citations (PDF) |
| 11 | Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101) | 6.8 | 14 | Citations (PDF) |
| 12 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity | 6.8 | 143 | Citations (PDF) |
| 13 | Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma | 4.9 | 91 | Citations (PDF) |
| 14 | Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma | 6.8 | 24 | Citations (PDF) |
| 15 | Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma | 6.8 | 24 | Citations (PDF) |
| 16 | Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial | 4.9 | 24 | Citations (PDF) |
| 17 | Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma | 25.1 | 62 | Citations (PDF) |
| 18 | T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors | 13.7 | 172 | Citations (PDF) |
| 19 | Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) | 1.0 | 105 | Citations (PDF) |
| 20 | Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis 2021, 9, e002553 | | 60 | Citations (PDF) |
| 21 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events 2021, 9, e002435 | | 763 | Citations (PDF) |
| 22 | Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors 2021, 9, e002835 | | 14 | Citations (PDF) |
| 23 | Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study | 27.4 | 300 | Citations (PDF) |
| 24 | Intratumoral Immunotherapy—Update 2019 | 3.4 | 144 | Citations (PDF) |
| 25 | Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma | 14.3 | 57 | Citations (PDF) |
| 26 | Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer | 5.5 | 86 | Citations (PDF) |
| 27 | Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma | 6.8 | 19 | Citations (PDF) |
| 28 | Observational Study Of Talimogene Laherparepvec Use in the Anti-PD-1 era for Melanoma in the US (COSMUS-2) | 0.6 | 9 | Citations (PDF) |
| 29 | COVID-19 and Cancer: a Comprehensive Review | 4.2 | 245 | Citations (PDF) |
| 30 | <p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p> | 2.7 | 6 | Citations (PDF) |
| 31 | Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study 2020, 8, e000331 | | 107 | Citations (PDF) |
| 32 | Pan-Cancer Efficacy of Vemurafenib in
BRAF
V600-Mutant Non-Melanoma Cancers | 25.1 | 125 | Citations (PDF) |
| 33 | Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
BRAF
-Mutant Melanoma | 6.8 | 40 | Citations (PDF) |
| 34 | Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study | 4.0 | 147 | Citations (PDF) |
| 35 | The great debate at “Immunotherapy Bridge 2018”, Naples, November 29th, 2018 2019, 7, | | 4 | Citations (PDF) |
| 36 | Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma | 5.5 | 30 | Citations (PDF) |
| 37 | Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) 2019, 7, | | 19 | Citations (PDF) |
| 38 | Clinical characterization of colitis arising from anti-PD-1 based therapy | 5.4 | 63 | Citations (PDF) |
| 39 | Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial | 27.4 | 351 | Citations (PDF) |
| 40 | Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma | 4.4 | 42 | Citations (PDF) |
| 41 | Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors | 2.5 | 73 | Citations (PDF) |
| 42 | Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours | 2.5 | 8 | Citations (PDF) |
| 43 | Circulating T-Cell Biomarkers to Predict Response to Immune Checkpoint Inhibitors | 0.7 | 0 | Citations (PDF) |
| 44 | Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | 16.9 | 3,453 | Citations (PDF) |
| 45 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma | 16.9 | 593 | Citations (PDF) |
| 46 | Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study | 1.9 | 28 | Citations (PDF) |
| 47 | Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses | 13.7 | 126 | Citations (PDF) |
| 48 | Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) 2018, 6, | | 12 | Citations (PDF) |
| 49 | Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden 2018, 6, | | 141 | Citations (PDF) |
| 50 | Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | 34.5 | 1,246 | Citations (PDF) |
| 51 | Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology | 12.6 | 251 | Citations (PDF) |
| 52 | Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma 2017, 5, | | 81 | Citations (PDF) |
| 53 | Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma | 6.8 | 69 | Citations (PDF) |
| 54 | Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition | 2.3 | 89 | Citations (PDF) |
| 55 | Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy 2017, 5, | | 129 | Citations (PDF) |
| 56 | Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyCell, 2017, 170, 1109-1119.e10 | 33.6 | 1,401 | Citations (PDF) |
| 57 | A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status | 2.6 | 27 | Citations (PDF) |
| 58 | Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E | 1.5 | 25 | Citations (PDF) |
| 59 | A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases | 2.5 | 11 | Citations (PDF) |
| 60 | Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma | 4.9 | 207 | Citations (PDF) |
| 61 | Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials 2017, 5, | | 43 | Citations (PDF) |
| 62 | Comparative analysis of the GNAQ,GNA11,SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum | 2.8 | 23 | Citations (PDF) |
| 63 | Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma | 2.3 | 13 | Citations (PDF) |
| 64 | Pembrolizumab for the treatment of advanced melanoma | 1.0 | 15 | Citations (PDF) |
| 65 | Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma | 4.9 | 92 | Citations (PDF) |
| 66 | Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade | 4.2 | 469 | Citations (PDF) |
| 67 | A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma | 2.8 | 14 | Citations (PDF) |
| 68 | The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma | 4.0 | 282 | Citations (PDF) |
| 69 | Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy | 13.7 | 545 | Citations (PDF) |
| 70 | Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction 2016, 4, | | 66 | Citations (PDF) |
| 71 | Fulminant Myocarditis with Combination Immune Checkpoint Blockade | 34.5 | 2,163 | Citations (PDF) |
| 72 | Treatment of elderly patients with melanoma | 0.2 | 0 | Citations (PDF) |
| 73 | Talimogene laherparepvec in advanced melanoma | 1.0 | 0 | Citations (PDF) |
| 74 | Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial | 2.3 | 289 | Citations (PDF) |
| 75 | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial | 27.4 | 403 | Citations (PDF) |
| 76 | Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders | 14.3 | 604 | Citations (PDF) |
| 77 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | 62.1 | 601 | Citations (PDF) |
| 78 | Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti–PD-1 Therapy | 4.2 | 21 | Citations (PDF) |
| 79 | Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket StudyBlood, 2016, 128, 480-480 | 4.8 | 7 | Citations (PDF) |
| 80 | Thyroid nodule: not as clear-cut as it seems | 0.1 | 1 | Citations (PDF) |
| 81 | Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab | 2.8 | 132 | Citations (PDF) |
| 82 | Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression | 4.9 | 68 | Citations (PDF) |
| 83 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | 16.9 | 2,501 | Citations (PDF) |
| 84 | A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors | 6.8 | 96 | Citations (PDF) |
| 85 | Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor | 34.5 | 549 | Citations (PDF) |
| 86 | Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center | 4.2 | 101 | Citations (PDF) |
| 87 | Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma | 1.9 | 186 | Citations (PDF) |
| 88 | Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | 27.4 | 1,547 | Citations (PDF) |
| 89 | Treatment of NRAS-Mutant Melanoma | 3.9 | 130 | Citations (PDF) |
| 90 | Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) | 6.4 | 29 | Citations (PDF) |
| 91 | Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients | 5.5 | 97 | Citations (PDF) |
| 92 | Vemurafenib in Multiple Nonmelanoma Cancers with
BRAF
V600 Mutations | 34.5 | 1,703 | Citations (PDF) |
| 93 | Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors | 6.8 | 19 | Citations (PDF) |
| 94 | Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy | 2.5 | 123 | Citations (PDF) |
| 95 | Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket StudyBlood, 2015, 126, 4263-4263 | 4.8 | 9 | Citations (PDF) |
| 96 | LK or IGF1R: When selectivity hurts | 0.9 | 0 | Citations (PDF) |
| 97 | A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma | 4.0 | 112 | Citations (PDF) |
| 98 | Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma | 16.5 | 347 | Citations (PDF) |
| 99 | Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study 2014, 2, | | 55 | Citations (PDF) |
| 100 | Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel | 3.4 | 102 | Citations (PDF) |
| 101 | Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study | 27.4 | 245 | Citations (PDF) |
| 102 | Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors | 2.5 | 55 | Citations (PDF) |
| 103 | γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000) | 6.8 | 65 | Citations (PDF) |
| 104 | Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases | 0.4 | 4 | Citations (PDF) |
| 105 | BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition | 6.8 | 173 | Citations (PDF) |
| 106 | A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma | 2.3 | 26 | Citations (PDF) |
| 107 | Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences? | 3.4 | 26 | Citations (PDF) |
| 108 | Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors | 6.8 | 31 | Citations (PDF) |
| 109 | Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations | 34.5 | 2,649 | Citations (PDF) |
| 110 | Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib | 34.5 | 2,038 | Citations (PDF) |
| 111 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | 27.4 | 1,055 | Citations (PDF) |
| 112 | RAS
Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors | 34.5 | 1,037 | Citations (PDF) |
| 113 | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | 27.4 | 892 | Citations (PDF) |
| 114 | Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors | 0.2 | 0 | Citations (PDF) |
| 115 | Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy | 4.0 | 46 | Citations (PDF) |
| 116 | Vemurafenib (RG67204, PLX4032): A Potent, Selective BRAF Kinase Inhibitor | 2.3 | 24 | Citations (PDF) |
| 117 | Biological challenges of BRAF inhibitor therapy | 4.1 | 33 | Citations (PDF) |
| 118 | Insulin‐like growth factor‐1 receptor inhibitor, AMG‐479, in cetuximab‐refractory head and neck squamous cell carcinoma | 2.0 | 17 | Citations (PDF) |
| 119 | Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors | 6.8 | 52 | Citations (PDF) |
| 120 | B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma | 4.2 | 51 | Citations (PDF) |
| 121 | Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma | 5.1 | 16 | Citations (PDF) |
| 122 | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | 37.9 | 1,767 | Citations (PDF) |
| 123 | A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets | 6.8 | 37 | Citations (PDF) |
| 124 | Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | 34.5 | 3,421 | Citations (PDF) |
| 125 | Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma | 2.3 | 48 | Citations (PDF) |
| 126 | Determination of chemically reduced pyrrolobenzodiazepine SJG‐136 in human plasma by HPLC‐MS/MS: application to an anticancer phase I dose escalation study | 1.7 | 9 | Citations (PDF) |
| 127 | Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group | 16.9 | 241 | Citations (PDF) |
| 128 | Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib | 3.4 | 339 | Citations (PDF) |
| 129 | Molecular Targets in Melanoma from Angiogenesis to Apoptosis | 6.8 | 46 | Citations (PDF) |
| 130 | Abstract C022: T-cell IL-6 expression defines a subset of memory T cells, and correlates with response to immune checkpoint inhibitors in patients with melanoma | 4.2 | 0 | Citations (PDF) |
| 131 | Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management | 4.9 | 1 | Citations (PDF) |
| 132 | Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis | 3.2 | 1 | Citations (PDF) |
